Topotarget UK Limited
Records under this name other than the patents Topotarget UK Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,828,392 | Histone Deacetylase (HDAC) Inhibitors (PXD101) for the Treatment of Cancer Alone or in Combination with Chemotherapeutic Agent Term ended Term ended Nov 10, 2026 · High confidence | Term ended | Term ended Nov 10, 2026 | High confidence |
| US 9,603,926 | Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer Term ended Term ended Nov 10, 2026 · High confidence | Term ended | Term ended Nov 10, 2026 | High confidence |
| US 9,980,957 | Histone deacetylase (HDAC) inhibitors for the treatment of cancer Term ended Term ended Nov 10, 2026 · USPTO record | Term ended | Term ended Nov 10, 2026 | USPTO record |
| US 6,888,027 | Carbamic Acid Compounds Comprising a Sulfonamide Linkage as Hdac Inhibitors Term ended Term ended Aug 10, 2026 · High confidence | Term ended | Term ended Aug 10, 2026 | High confidence |
| US 9,856,211 | Pharmaceutical formulations of HDAC inhibitors Term ended Term ended May 11, 2026 · USPTO record | Term ended | Term ended May 11, 2026 | USPTO record |
| US 9,957,227 | Pharmaceutical formulations of HDAC inhibitors Term ended Term ended May 11, 2026 · USPTO record | Term ended | Term ended May 11, 2026 | USPTO record |
| US 10,285,959 | Combination Therapies Using Hdac Inhibitors Term ended Term ended Feb 3, 2026 · Medium confidence | Term ended | Term ended Feb 3, 2026 | Medium confidence |
| US 10,799,469 | Combination Therapies Using HDAC Inhibitors Lapsed on the fee record Ended Oct 13, 2024 · High confidence | Lapsed on the fee record | Ended Oct 13, 2024 | High confidence |
| US 7,981,895 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors Term ended Term ended Apr 3, 2023 · USPTO record | Term ended | Term ended Apr 3, 2023 | USPTO record |
| US 7,183,298 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors Term ended Term ended Jun 1, 2022 · USPTO record | Term ended | Term ended Jun 1, 2022 | USPTO record |